5 Key Takeaways

• 1

  There is a significant gap between therapeutic innovation in glaucoma and the ability to conduct robust testing of treatments.

• 2

  Collaborative networks among clinicians and surgeons are essential for addressing shared questions in glaucoma research.

• 3

  Registry-based randomized controlled trials could streamline data collection and enhance participation in glaucoma studies.

• 4

  New statistical tools like Fragility Indices and WIN ratios are gaining traction and may improve trial reporting and outcome measurement.

• 5

  AI is expected to assist in complex analyses but many improvements in glaucoma care can be achieved with existing knowledge.